ASSESSING 2-MONTH CLINICAL PROGNOSIS IN PATIENTS WITH SOLID TUMORS: RESULTS OF PRONOPALL STUDY

Palliative cancer therapy is a difficult medical practice, particularly in the advanced stages of the disease. Relevance puts repeatedly question to medical oncologists. The prognostic evaluation could be an aid to therapeutic decision, especially in a palliative context, where chemotherapy can degrade quality of life of patients. Oncologists, caregivers and close relatives can be brought to challenge the risk of harmful or unnecessary chemotherapy. Indeed, a toxic death deprives patient, family and teams to do preparatory work necessary in later life.

The Palliative Care team from Poitiers’s UHC validated a prognostic score in a population of hospitalized patients. The Observatory dedicated to Cancer from Brittany and Pays de la Loire areas wants to validate this score in an outpatient population during consultation.

### Prognostic Scoring

* October 2009 - November 2010: 302 patients included  
  - 265 evaluable patients; 37 patients not eligible.

* 109 Males / 156 Females

* median age: 66 years [37-88]

* 80% of the patients had a previous palliative anticancer treatment

* Prognostic criteria for inclusion:
  - 1 criterion for 46% of patients
  - 2 criteria for 38% of patients
  - 3 criteria for 16% of patients

### Survival

<table>
<thead>
<tr>
<th>Population</th>
<th>Median Overall Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Score 8-10</td>
<td>74 days [51 - 113]</td>
</tr>
<tr>
<td>Score 4-7</td>
<td>78 days [71 - 113]</td>
</tr>
<tr>
<td>Score 0-3</td>
<td>301 days [209 - 348]</td>
</tr>
</tbody>
</table>

### Palliasmin Phase

* Palliasmin phase and validation in current practice coming soon...
* Prognostic score validated in 2 phases: Palliasmin and validation in current practice.

### Oncogeriatry

* 62 patients over 75 years

* Inclusion criteria: no statistically significant between <75 and >75 years patients except for the distribution of the primary tumor

* Same distribution of the score values

### Distribution survival curves of the 2 populations

Statistically significant influence on the survival curve of n<0.0001:
- Performance Status
- LDH rate
- Albumin rate

### Palliasmin Phase

* Prognostic score validated in 2 phases: Palliasmin and validation in current practice.

### Results from Palliasmin phase and validation in current practice coming soon...